Cannara Biotech Inc. (LOVE) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

everyone and welcome to canara biotech's fiscal year q2 earnings presentation for the three and six months ended february 28 2025. my name is scott carroll and i will act as a moderator for today's presentation as a reminder this presentation is being recorded following prepared remarks we will conduct a question and answer session if you haven't already done so you may submit your questions to investors canara.ca or in the chat option in your conference browser. Should all submitted questions be addressed today, we will follow up accordingly via email. Before we begin, please refer to slides two and three of our presentation. All information presented today is subject to our general disclaimers on financial measures and forward-looking statements, which are also available to be read in detail at cdarplus.ca. I will now turn over the call to Nicholas Sosiak, Chief Financial Officer. Good morning, everyone. Thank you again for joining our Q2 Earnings webcast. My name is Nicholas Soziak, and as CFO of Canara, I have been deeply involved in every aspect of this company since 2019. From cultivation to processing, finance, strategy, sales and marketing, and product development, we're working alongside our team to drive success. I'm deeply proud of Canara for being one of Canada's largest vertically integrated cannabis producers, driven by strong financials, innovation, and a consumer-first approach. What truly gives Canara its competitive edge is our control and execution. We've built one of the most cost-efficient operations in the industry, while maintaining market-leading quality. As this is our first public quarterly earnings presentation, I will provide a brief summary of who we are and where we are going, as well as the underlying competitive advantages within our b...